Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
3 recherche sur le mot-clé 'case-control study'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Association of urinary polycyclic aromatic hydrocarbon metabolites with symptoms among autistic children: A case-control study in Tianjin, China / Peiying LI in Autism Research, 15-10 (October 2022)
[article]
Titre : Association of urinary polycyclic aromatic hydrocarbon metabolites with symptoms among autistic children: A case-control study in Tianjin, China Type de document : Texte imprimé et/ou numérique Auteurs : Peiying LI, Auteur ; Qiaoyun YANG, Auteur ; Yao LI, Auteur ; Yu HAN, Auteur ; Zhiyi QU, Auteur ; Lei GAO, Auteur ; Tingkai CUI, Auteur ; Wenjuan XIONG, Auteur ; Wei XI, Auteur ; Xin ZHANG, Auteur Article en page(s) : p.1941-1960 Langues : Anglais (eng) Mots-clés : autism spectrum disorder behavioral characteristics case-control study children internal exposure polycyclic aromatic hydrocarbon Index. décimale : PER Périodiques Résumé : Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous pollutants that are associated with altered neurodevelopment and various neurodevelopmental disorders. However, studies evaluating internal biomarkers of PAH exposure in reference to the severity of autism spectrum disorder (ASD) symptomology and autistic behaviors are scarce. Hence, we conducted a case-control study evaluating 12 urinary hydroxylated PAH metabolites (i.e., hydroxy-PAHs) in 101 children with autism and 101 neurotypical children, matching according to sex and age in a 1:1 ratio. In children with ASD, the severity of symptomology and autistic behaviors were assessed using the child autism rating scale (CARS) and the autism behavior checklist (ABC). We found that urinary levels of nine of the hydroxy-PAHs were statistically significantly higher in the ASD group, with the exception of 2-hydroxynaphthalene (2-OHNap) and 4-hydroxyphenanthrene (4-OHPhe). Moreover, urinary hydroxy-PAH levels were associated with ASD risk, with odds ratios ranging from 1.86 to 17.19. Exposures to 1-hydroxynaphthalene (1-OHNap,Î2 = 3.32), hydroxyphenanthrenes (1/2/3 + 9-OHPhes,Î2 = 3.41-5.12), 1-hydroxypyrene (1-OH-Pyr;Î2 = 3.91), 2-hydroxybenzofuran (2-OHDBF;Î2 = 3.93), and â‘OH-PAHs (Î2 = 4.67) were positively associated with CARS scores after adjusting for covariates (all p< 0.05). When applying the ABC scale, 1-OHPyr levels were positively associated with ABC total scores (Î2 = 18.54), with the strongest associations evidenced in regard to the social relatedness (Î2 = 6.51) and language domains (Î2 = 6.51) (all p< 0.05). Bayesian kernel machine regression (BKMR) showed consistent positive exposure responses for 1-OHNap, 1-OHPhe, and 3 + 9-OHPhe levels in regard to CARS scores, and for 1-OHPyr levels in regard to ABC total scores. Our findings suggest that children with ASD may have higher urinary levels of hydroxy-PAHs, and that these biomarker levels are associated with an increased odds of ASD, an increased severity of autism symptomology, and increased autistic behaviors in children with autism. LAY SUMMARY: We conducted an epidemiologic study evaluating the associations of urinary hydroxy-PAH levels with autism spectrum disorder (ASD), autism symptomology, and autistic behaviors. We found that urinary hydroxy-PAHs were statistically significantly associated with ASD. We note strong statistically significant associations between 1-OHNap, 1-OHPhe, and 3 + 9-OHPhe levels and increased severity of autism symptomology, as well as a strong statistically significant association between 1-OHPyr levels and behavioral characteristics within the social and linguistic domains. This work, if confirmed, will contribute to the future development of diagnostics for children with mild autism, as well as to environmental measures to promote the health and wellbeing of children with autism spectrum disorders. En ligne : http://dx.doi.org/10.1002/aur.2788 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=488
in Autism Research > 15-10 (October 2022) . - p.1941-1960[article] Association of urinary polycyclic aromatic hydrocarbon metabolites with symptoms among autistic children: A case-control study in Tianjin, China [Texte imprimé et/ou numérique] / Peiying LI, Auteur ; Qiaoyun YANG, Auteur ; Yao LI, Auteur ; Yu HAN, Auteur ; Zhiyi QU, Auteur ; Lei GAO, Auteur ; Tingkai CUI, Auteur ; Wenjuan XIONG, Auteur ; Wei XI, Auteur ; Xin ZHANG, Auteur . - p.1941-1960.
Langues : Anglais (eng)
in Autism Research > 15-10 (October 2022) . - p.1941-1960
Mots-clés : autism spectrum disorder behavioral characteristics case-control study children internal exposure polycyclic aromatic hydrocarbon Index. décimale : PER Périodiques Résumé : Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous pollutants that are associated with altered neurodevelopment and various neurodevelopmental disorders. However, studies evaluating internal biomarkers of PAH exposure in reference to the severity of autism spectrum disorder (ASD) symptomology and autistic behaviors are scarce. Hence, we conducted a case-control study evaluating 12 urinary hydroxylated PAH metabolites (i.e., hydroxy-PAHs) in 101 children with autism and 101 neurotypical children, matching according to sex and age in a 1:1 ratio. In children with ASD, the severity of symptomology and autistic behaviors were assessed using the child autism rating scale (CARS) and the autism behavior checklist (ABC). We found that urinary levels of nine of the hydroxy-PAHs were statistically significantly higher in the ASD group, with the exception of 2-hydroxynaphthalene (2-OHNap) and 4-hydroxyphenanthrene (4-OHPhe). Moreover, urinary hydroxy-PAH levels were associated with ASD risk, with odds ratios ranging from 1.86 to 17.19. Exposures to 1-hydroxynaphthalene (1-OHNap,Î2 = 3.32), hydroxyphenanthrenes (1/2/3 + 9-OHPhes,Î2 = 3.41-5.12), 1-hydroxypyrene (1-OH-Pyr;Î2 = 3.91), 2-hydroxybenzofuran (2-OHDBF;Î2 = 3.93), and â‘OH-PAHs (Î2 = 4.67) were positively associated with CARS scores after adjusting for covariates (all p< 0.05). When applying the ABC scale, 1-OHPyr levels were positively associated with ABC total scores (Î2 = 18.54), with the strongest associations evidenced in regard to the social relatedness (Î2 = 6.51) and language domains (Î2 = 6.51) (all p< 0.05). Bayesian kernel machine regression (BKMR) showed consistent positive exposure responses for 1-OHNap, 1-OHPhe, and 3 + 9-OHPhe levels in regard to CARS scores, and for 1-OHPyr levels in regard to ABC total scores. Our findings suggest that children with ASD may have higher urinary levels of hydroxy-PAHs, and that these biomarker levels are associated with an increased odds of ASD, an increased severity of autism symptomology, and increased autistic behaviors in children with autism. LAY SUMMARY: We conducted an epidemiologic study evaluating the associations of urinary hydroxy-PAH levels with autism spectrum disorder (ASD), autism symptomology, and autistic behaviors. We found that urinary hydroxy-PAHs were statistically significantly associated with ASD. We note strong statistically significant associations between 1-OHNap, 1-OHPhe, and 3 + 9-OHPhe levels and increased severity of autism symptomology, as well as a strong statistically significant association between 1-OHPyr levels and behavioral characteristics within the social and linguistic domains. This work, if confirmed, will contribute to the future development of diagnostics for children with mild autism, as well as to environmental measures to promote the health and wellbeing of children with autism spectrum disorders. En ligne : http://dx.doi.org/10.1002/aur.2788 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=488 Birth weight and autism spectrum disorder: A population-based nested case-control study / Ziv TALMI in Autism Research, 13-4 (April 2020)
[article]
Titre : Birth weight and autism spectrum disorder: A population-based nested case-control study Type de document : Texte imprimé et/ou numérique Auteurs : Ziv TALMI, Auteur ; David MANKUTA, Auteur ; Raanan RAZ, Auteur Article en page(s) : p.655-665 Langues : Anglais (eng) Mots-clés : autism spectrum disorder birth weight case-control study epidemiology perinatal risk factors Index. décimale : PER Périodiques Résumé : Low birth weight (<2,500 g) and preterm birth (<37 weeks) were found to be associated with increased risk of autism spectrum disorder (ASD), however, the data regarding the entire birth weight (BW) and gestational age (GA) range are inconclusive. In this population nested case-control study, based on the Israeli National Insurance Institute records, we aimed to estimate the associations in the Israeli population. The study population included all children born between 2000 and 2012 and diagnosed with ASD (N = 12,635 cases), and a random 20% sample of children born in the same period who were not diagnosed with ASD (N = 369,548 controls). We used multiple logistic regression models to calculate the risk of ASD for each BW and GA category, adjusted for covariates (child sex, maternal age, paternal age, population group, maternal wage, paternal wage, having a sibling with ASD, multiple gestation and socioeconomic status). BW < 3,000 g and GA < 39 weeks were associated with higher risk of ASD, including BW of 2,500-3,000 g (adjusted odds ratio [AOR], 1.18; 95% CI, 1.12-1.24, in comparison to the 3,000-3,500 g category) and GA of 37 & 38 weeks (AOR, 1.35; 95% CI, 1.25-1.45 and AOR, 1.13; 95% CI 1.06-1.20, respectively; in comparison to GA of 40 weeks). To account for the high correlation between GA and BW, we modeled BW percentiles for gestational age and found that the BW < 20th percentile was associated with an increased risk of ASD (AOR, 1.10; 95% CI, 1.01-1.19). These results demonstrate that associations of ASD with BW and GA are not limited to commonly used clinical cutoffs. Autism Res 2020, 13: 655-665. (c) 2020 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Autism spectrum disorder (ASD) has been associated with low birth weight (<2,500 g) in prior research. Our study aims to describe the relationship between birth weight (BW) and ASD in the Israeli population. We found that BW <3,000 g was associated with a higher risk of ASD. These results demonstrate that an increased risk of ASD is not confined to clinically defined cutoffs such as BW < 2,500 g. En ligne : http://dx.doi.org/10.1002/aur.2260 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421
in Autism Research > 13-4 (April 2020) . - p.655-665[article] Birth weight and autism spectrum disorder: A population-based nested case-control study [Texte imprimé et/ou numérique] / Ziv TALMI, Auteur ; David MANKUTA, Auteur ; Raanan RAZ, Auteur . - p.655-665.
Langues : Anglais (eng)
in Autism Research > 13-4 (April 2020) . - p.655-665
Mots-clés : autism spectrum disorder birth weight case-control study epidemiology perinatal risk factors Index. décimale : PER Périodiques Résumé : Low birth weight (<2,500 g) and preterm birth (<37 weeks) were found to be associated with increased risk of autism spectrum disorder (ASD), however, the data regarding the entire birth weight (BW) and gestational age (GA) range are inconclusive. In this population nested case-control study, based on the Israeli National Insurance Institute records, we aimed to estimate the associations in the Israeli population. The study population included all children born between 2000 and 2012 and diagnosed with ASD (N = 12,635 cases), and a random 20% sample of children born in the same period who were not diagnosed with ASD (N = 369,548 controls). We used multiple logistic regression models to calculate the risk of ASD for each BW and GA category, adjusted for covariates (child sex, maternal age, paternal age, population group, maternal wage, paternal wage, having a sibling with ASD, multiple gestation and socioeconomic status). BW < 3,000 g and GA < 39 weeks were associated with higher risk of ASD, including BW of 2,500-3,000 g (adjusted odds ratio [AOR], 1.18; 95% CI, 1.12-1.24, in comparison to the 3,000-3,500 g category) and GA of 37 & 38 weeks (AOR, 1.35; 95% CI, 1.25-1.45 and AOR, 1.13; 95% CI 1.06-1.20, respectively; in comparison to GA of 40 weeks). To account for the high correlation between GA and BW, we modeled BW percentiles for gestational age and found that the BW < 20th percentile was associated with an increased risk of ASD (AOR, 1.10; 95% CI, 1.01-1.19). These results demonstrate that associations of ASD with BW and GA are not limited to commonly used clinical cutoffs. Autism Res 2020, 13: 655-665. (c) 2020 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Autism spectrum disorder (ASD) has been associated with low birth weight (<2,500 g) in prior research. Our study aims to describe the relationship between birth weight (BW) and ASD in the Israeli population. We found that BW <3,000 g was associated with a higher risk of ASD. These results demonstrate that an increased risk of ASD is not confined to clinically defined cutoffs such as BW < 2,500 g. En ligne : http://dx.doi.org/10.1002/aur.2260 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421 Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders / Mark J. ZYLKA in Autism Research, 13-1 (January 2020)
[article]
Titre : Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders Type de document : Texte imprimé et/ou numérique Auteurs : Mark J. ZYLKA, Auteur Article en page(s) : p.11-17 Langues : Anglais (eng) Mots-clés : autism spectrum disorder birth weight case-control study epidemiology risk markers Index. décimale : PER Périodiques Résumé : Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by mutation or deletion of the maternally inherited UBE3A allele. These pathogenic mutations lead to loss of maternal UBE3A expression in neurons. Antisense oligonucleotides and gene therapies are in development, which activate the intact but epigenetically silenced paternal UBE3A allele. Preclinical studies indicate that treating during the prenatal period could greatly reduce the severity of symptoms or prevent AS from developing. Genetic tests can detect the chromosome 15q11-q13 deletion that is the most common cause of AS. New, highly sensitive noninvasive prenatal tests that take advantage of single-cell genome sequencing technologies are expected to enter the clinic in the coming years and make early genetic diagnosis of AS more common. Efforts are needed to identify fetuses and newborns with maternal 15q11-q13 deletions and to phenotype these babies relative to neurotypical controls. Clinical and parent observations suggest AS symptoms are detectable in infants, including reports of problems with feeding and motor function. Quantitative phenotypes in the 0- to 1-year age range will permit a more rapid assessment of efficacy when future treatments are administered prenatally or shortly after birth. Although prenatal therapies are currently not available for AS, prenatal testing combined with prenatal treatment has the potential to revolutionize how clinicians detect and treat babies before they are symptomatic. This pioneering prenatal treatment path for AS will lay the foundation for treating other syndromic neurodevelopmental disorders. Autism Res 2020, 13: 11-17. (c) 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Prenatal treatment could benefit expectant parents whose babies test positive for the chromosome microdeletion that causes Angelman syndrome (AS). Prenatal treatment is predicted to have better outcomes than treating after symptoms develop and may even prevent AS altogether. This approach could generally be applied to the treatment of other syndromic neurodevelopmental disorders. En ligne : http://dx.doi.org/10.1002/aur.2203 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=415
in Autism Research > 13-1 (January 2020) . - p.11-17[article] Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders [Texte imprimé et/ou numérique] / Mark J. ZYLKA, Auteur . - p.11-17.
Langues : Anglais (eng)
in Autism Research > 13-1 (January 2020) . - p.11-17
Mots-clés : autism spectrum disorder birth weight case-control study epidemiology risk markers Index. décimale : PER Périodiques Résumé : Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by mutation or deletion of the maternally inherited UBE3A allele. These pathogenic mutations lead to loss of maternal UBE3A expression in neurons. Antisense oligonucleotides and gene therapies are in development, which activate the intact but epigenetically silenced paternal UBE3A allele. Preclinical studies indicate that treating during the prenatal period could greatly reduce the severity of symptoms or prevent AS from developing. Genetic tests can detect the chromosome 15q11-q13 deletion that is the most common cause of AS. New, highly sensitive noninvasive prenatal tests that take advantage of single-cell genome sequencing technologies are expected to enter the clinic in the coming years and make early genetic diagnosis of AS more common. Efforts are needed to identify fetuses and newborns with maternal 15q11-q13 deletions and to phenotype these babies relative to neurotypical controls. Clinical and parent observations suggest AS symptoms are detectable in infants, including reports of problems with feeding and motor function. Quantitative phenotypes in the 0- to 1-year age range will permit a more rapid assessment of efficacy when future treatments are administered prenatally or shortly after birth. Although prenatal therapies are currently not available for AS, prenatal testing combined with prenatal treatment has the potential to revolutionize how clinicians detect and treat babies before they are symptomatic. This pioneering prenatal treatment path for AS will lay the foundation for treating other syndromic neurodevelopmental disorders. Autism Res 2020, 13: 11-17. (c) 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Prenatal treatment could benefit expectant parents whose babies test positive for the chromosome microdeletion that causes Angelman syndrome (AS). Prenatal treatment is predicted to have better outcomes than treating after symptoms develop and may even prevent AS altogether. This approach could generally be applied to the treatment of other syndromic neurodevelopmental disorders. En ligne : http://dx.doi.org/10.1002/aur.2203 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=415